Xeris Pharmaceuticals | XERS

Stock Price
7.85
Daily Change
-0.04 -0.51%
Monthly
42.99%
Yearly
212.75%
Q3 Forecast
7.78

Peers Price Chg Day Year Date
Celltrion 169,000.00 -1,200.00 -0.71% -11.61% Sep/05
Cspc Pharmaceutical 11.19 0.36 3.32% 140.13% Sep/05
Sino Biopharmaceutical 8.91 0.52 6.20% 183.76% Sep/05
Zhangzhou Pientzehuang Pharmaceutical 203.87 0.94 0.46% 0.69% Sep/05
Kangmei Pharma 2.03 0 0% 15.34% Sep/05
Adcock Ingram Holdings 7,187.00 -13.00 -0.18% 10.77% Sep/05
Divis Laboratories Ltd 6,009.00 -124.50 -2.03% 16.96% Sep/05
Knight Therapeutics 6.44 0 0% 14.18% Sep/05
Eli Lilly 727.21 -15.70 -2.11% -19.48% Sep/05
Dianthus Therapeutics 26.50 1.84 7.46% -0.45% Sep/05
Malin Corporation 8.00 0 0% 29.03% Sep/01
Medical Developments International 0.58 -0.01 -0.86% 36.90% Sep/05
Neuren Pharmaceuticals 20.48 0.50 2.50% 51.03% Sep/05
Organigram Holdings 2.28 0.08 3.64% -4.20% Sep/05
Pacira 26.45 -0.28 -1.05% 90.97% Sep/05
Pharma Mar 88.40 -2.80 -3.07% 116.88% Sep/05
Perrigo 23.49 -0.25 -1.05% -19.14% Sep/02
Qiagen NV 40.39 0.18 0.44% -1.38% Sep/06
Laboratorios Farma 59.65 -0.10 -0.17% -26.18% Sep/05
Sartorius 193.20 4.90 2.60% -23.42% Sep/06
Supernus Pharmaceuticals 46.00 0.57 1.25% 35.93% Sep/05
Tilray 1.64 0.06 3.80% -25.45% Sep/05


Xeris Pharmaceuticals Inc traded at $7.85 this Friday September 5th, decreasing $0.04 or 0.51 percent since the previous trading session. Looking back, over the last four weeks, Xeris Pharmaceuticals lost 42.99 percent. Over the last 12 months, its price rose by 212.75 percent. Looking ahead, we forecast Xeris Pharmaceuticals Inc to be priced at 7.78 by the end of this quarter and at 7.59 in one year, according to Trading Economics global macro models projections and analysts expectations.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which is focused on improving patients’ lives by developing and commercializing products across a range of therapies. It has three commercial products. Gvoke is a ready-to-use, liquid-stable glucagon for the treatment of severe hypoglycemia. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Keveyis is the first therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis (PPP). It also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect. Its product candidate XP-8121, which is designed to be a once-weekly, small-volume, subcutaneous injection that bypasses the gastrointestinal tract and could avoid many therapeutic complications.